| Literature DB >> 27573046 |
Sun Hee Hwang1, Eun Ja Kim1, Young Bin Hong2, Jaesoon Joo1, Sung Min Kim3, Soo Hyun Nam3, Hyun Dae Hong3, Seung Hyun Kim4, Kiwook Oh4, Jeong-Geun Lim5, Jeong Hee Cho6, Ki Wha Chung3, Byung-Ok Choi1.
Abstract
Mutations in the Dynactin 1 (DCTN1) gene have been demonstrated to result in various neurodegenerative diseases, including distal hereditary motor neuropathy type 7B (dHMN7B), Perry syndrome, amyotrophic lateral sclerosis and amyotrophic lateral sclerosis‑frontotemporal dementia. However, since the first dHMN7B patient with a DCTN1 mutation was described in 2003, to the best of our knowledge no further cases have been reported. In the present study, the DCTN1 p.G59S mutation was identified in two unrelated families from a total of 24 Korean families with dHMN, by whole exome sequencing. Codon 59 appears to be the mutational hot spot in the DCTN1 gene, as all described dHMN7B patients to date have harbored an identical p.G59S mutation. The families of the present study with the DCTN1 mutation had a milder disease with a later onset compared with the previously described patients. No affected family members exhibited facial muscle weakness or bulbar involvement. One family member demonstrated vocal cord palsy as the initial sign of disease; however, in the other family hand muscle weakness was the first major symptom. No affected patients demonstrated sensory loss or upper motor neuron involvements. Although this is only the second report of dHMN7B resulting from a DCTN1 mutation, the frequency of the DCTN1 mutation was not low in the Korean population examined, and clinical heterogeneities were observed in patients with the DCTN1 mutation. Therefore, it may be beneficial to screen all dHMN patients for the DCTN1 mutation.Entities:
Mesh:
Year: 2016 PMID: 27573046 DOI: 10.3892/mmr.2016.5664
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952